Advertisement

Topics

Psoriatic Arthritis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 01072017] Prices from USD $2250

04:58 EDT 2 Aug 2017 | BioPortfolio Report Blog

DelveInsight's, Psoriatic Arthritis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 report provides comprehensive insights about marketed and Phase III products for the Psoriatic Arthritis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Psoriatic Arthritis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends.

The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary information and data has been collected from various printable and nonprintable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.

Scope

A review of the marketed products for Psoriatic Arthritis including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.
Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
API manufacturers for the marketed products with location details
Emerging Phase III product profiles for Psoriatic Arthritis including product description, developmental activities, licensors collaborators and chemical information

Reasons to Buy

API intelligence for marketed drugs for the indication and gaining insights of API manufacturers
Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development
Design effective counterstrategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication
Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space

Original Article: Psoriatic Arthritis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 01072017] Prices from USD $2250

NEXT ARTICLE

More From BioPortfolio on "Psoriatic Arthritis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 01072017] Prices from USD $2250"

Quick Search
Advertisement
 

Relevant Topics

Arthritis
Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...